Why Progesterone Accompanies Estrogen When the Uterus Is Intact
Placeholder: unopposed estrogen thickens the endometrium unchecked.
- ↑ 8x: Unopposed EE risk (Placeholder relative risk figure)
- Uterus intact: Applies when (Placeholder condition)
- Add progestin: Mitigation (Placeholder mitigation)
- Dose-dependent: Exposure duration (Placeholder note)
Unopposed estrogen risk
Placeholder: chronic estrogen exposure without progestin promotes hyperplasia.
Placeholder: progestin co-therapy is standard of care with a uterus.
How Progesterone Protects the Endometrium
Placeholder: progesterone opposes estrogen-driven glandular growth.
- Antiproliferative: Mechanism (Placeholder mechanism label)
- Endometrium: Target tissue (Placeholder tissue)
- PR-mediated: Receptor (Placeholder receptor note)
- Reduced hyperplasia: Outcome (Placeholder outcome)
Progesterone receptor action
Placeholder: progesterone promotes secretory transformation and shedding.
Placeholder: adequate dose and duration matter for protection.
Cyclic Versus Continuous Combined Regimens
Placeholder: two dosing schedules trade off bleeding for predictability.
- Monthly: Cyclic bleed (Placeholder pattern)
- Irregular→none: Continuous bleed (Placeholder pattern)
- ~12 months: Time to amenorrhea (Placeholder estimate)
- Varies: Patient preference (Placeholder note)
Scheduling tradeoffs
Placeholder: cyclic mimics a natural cycle; continuous avoids scheduled bleeds.
Placeholder: choice depends on patient tolerance for spotting.
Estrogen-Only Therapy After Hysterectomy
Placeholder: without a uterus, progestin adds no protective benefit.
- None: Progestin need (Placeholder condition)
- N/A: Endometrial risk (Placeholder — no endometrium)
- ET alone: Regimen (Placeholder label)
- Lower: Side-effect load (Placeholder comparison)
Simplified therapy
Placeholder: estrogen-only avoids unnecessary progestin exposure.
Placeholder: hysterectomy status simplifies regimen choice.
Choosing a Regimen From Patient Factors
Placeholder: uterus status and bleeding preference set the final regimen.
- Uterus status: Key input 1 (Placeholder factor)
- Regimen type: Key input 2 (Placeholder factor)
- Regimen match: Output (Placeholder result)
- Annual: Review cadence (Placeholder cadence)
Combining the factors
Placeholder: match therapy type to individual risk and preference.
Placeholder: shared decision-making guides final selection.